Egalet President and CEO Bob Radie Named EY Entrepreneur of the Year®

WAYNE, Penn., June 10, 2016 /PRNewswire/ — Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced today that president and chief executive officer Bob Radie has been named the Greater Philadelphia’s 2016 EY Entrepreneur of the Year® in healthcare.  

Mr. Radie was recognized because of his extraordinary leadership in the areas of innovation, financial performance and strategic direction, as well as for his personal influence, entrepreneurial spirit and impact on the Greater Philadelphia community. 

“Receiving this recognition truly is an honor that I share with the entire Egalet team whose hard work and dedication has been integral to the success of this company,” said Mr. Radie. “EY’s program is a tribute to the incredible talent and entrepreneurial spirit that makes up our great community and I’m honored to be in the company of many current and past Entrepreneur of the Year finalists and recipients.”

Regional award winners are eligible for consideration for the EY Entrepreneur of the Year National program. Award winners in several national categories, as well as the EY Entrepreneur of the Year National Overall Award winner, will be announced at the EY Entrepreneur of the Year National Awards gala in Palm Springs, California on November 19, 2016.

About EY Entrepreneur of the Year®
The EY Entrepreneur of the Year award program, which is celebrating its 30th year, recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment to their businesses and communities. The program recognizes business leaders in more than 145 cities in more than 60 countries throughout the world whose ingenuity and perseverance have created and sustained successful, growing business ventures.

About Egalet
Egalet, a fully integrated specialty pharmaceutical company, is focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions. Egalet has two approved products: OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII and SPRIX® (ketorolac tromethamine) Nasal Spray. In addition, using its proprietary Guardian™ Technology, Egalet is developing a pipeline of clinical-stage, product candidates that are specifically designed to deter abuse by physical and chemical manipulation. The lead programs, ARYMO™ ER, an abuse-deterrent, extended-release, oral morphine formulation, and Egalet-002, an abuse-deterrent, extended-release, oral oxycodone formulation, are being developed for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet’s Guardian Technology can be applied broadly across different classes of pharmaceutical products and can be used to develop combination products that include multiple active pharmaceutical ingredients with similar or different release profiles. For additional information on Egalet, please visit egalet.com. For full prescribing information on SPRIX, including the boxed warning, please visit sprix.com. For full prescribing information on OXAYDO, please visit oxaydo.com.

Safe Harbor
Statements included in this press release (including but not limited to upcoming milestones) that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: the success of Egalet’s clinical trials, including the timely recruitment of trial subjects and meeting the timelines therefor; Egalet’s ability to obtain regulatory approval of Egalet’s product candidates; Egalet’s ability to maintain the intellectual property position of Egalet’s products and product candidates; Egalet’s ability to identify and reliance upon qualified third parties to manufacture its products; Egalet’s ability to service its debt obligations; Egalet’s ability to find and hire qualified sales professionals; the receptivity in the marketplace and among physicians to Egalet’s products; the success of products which compete with Egalet’s that are or become available; general market conditions; and other risk factors described in Egalet’s filings with the United States Securities and Exchange Commission. Egalet assumes no obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.

Media and Investor Contact:
E. Blair Clark-Schoeb
Senior Vice President, Communications
Email: bcs@egalet.com
Tel: 917-432-9275

Logo – http://photos.prnewswire.com/prnh/20140219/NY67493LOGO

SOURCE Egalet Corporation

Leave a Reply

Your email address will not be published. Required fields are marked *